By Keith Loria
Enriched & Expanded Veterinary News Report

Executive Overview

For decades, a diagnosis of feline infectious peritonitis (FIP) was among the most devastating verdicts a veterinarian could deliver. Once considered uniformly fatal, this insidious and complex disease claimed the lives of countless cats, leaving owners with heartbreaking prognoses and few options beyond palliative care or euthanasia. Today, the landscape of feline medicine has radically shifted. The advent of targeted antiviral medications has transformed FIP from a death sentence into a treatable, and frequently curable, condition.

Yet, this therapeutic revolution has inadvertently cast a glaring spotlight on a persistent veterinary challenge: diagnostics. Despite monumental leaps in antiviral therapy, clinicians still lack a single, infallible, antemortem test capable of definitively confirming or excluding FIP in every patient.

This diagnostic uncertainty carries immense weight. In the era of life-saving antivirals, an ambiguous test result can delay critical treatment, subject a fragile cat to weeks of expensive and unnecessary medications for the wrong disease, or obscure an entirely different underlying pathology.

To bridge this critical gap, a team of veterinary researchers has evaluated an innovative diagnostic approach: multiplex fluorescent immunocytochemistry (MF-ICC). In a comprehensive new study, lead author Samantha J.M. Evans, DVM, PhD, DACVP, DACVM, and her collaborators assessed the efficacy of MF-ICC in cats presenting with clinical signs compatible with FIP. By detecting feline coronavirus antigen specifically within macrophages—the hallmark immune cells driving systemic FIP disease—without the need for invasive surgical biopsies, this method represents a promising leap forward.

While the assay emerged as the most accurate among four evaluated diagnostic strategies, researchers emphasize a crucial caveat: MF-ICC is not a silver bullet. Instead, it serves as a powerful new tool in a diagnostic arsenal that relies on synthesizing clinical signs, biochemical markers, and advanced laboratory techniques to build an airtight clinical case.

Detailed Chronology: The Evolution of FIP Diagnostics

To understand the significance of the MF-ICC assay, one must trace the historical evolution of FIP diagnostics and the persistent obstacles that have long plagued veterinary clinicians.

The Diagnostic Hurdle

Feline coronavirus (FCoV) is exceptionally common, particularly in multi-cat environments, catteries, and shelters. However, the vast majority of cats exposed to FCoV never develop FIP. The virus typically causes mild, transient enteric infections. FIP emerges only when the virus mutates and drives a devastating, systemic immune-mediated disease. This high background prevalence of harmless coronavirus exposure has historically crippled conventional diagnostic tests, which often detect exposure rather than true systemic disease.

Historically, clinicians have relied on a patchwork of testing methodologies:

• RT-PCR (Reverse Transcription-Polymerase Chain Reaction): Looks for viral RNA. While useful, it struggles to differentiate between benign enteric coronavirus shedding and the virulent systemic FIP mutation.
• Serology: Detects the cat’s antibody response to the coronavirus. High titers indicate exposure but cannot confirm systemic FIP.
• Biochemical Markers: The serum albumin-to-globulin ratio provides a valuable clue, as systemic FIP frequently causes hyperglobulinemia and hypoalbuminemia, lowering the ratio.
• Histopathology and Immunohistochemistry (IHC): Long considered the gold standard for a definitive diagnosis, these methods traditionally require examining tissue samples. In unstable, critically ill cats, obtaining these samples often necessitates invasive exploratory surgery—a dangerous proposition for a compromised patient.

Enter MF-ICC: A Smarter Way to Look Inside Cells

Recognizing the limitations of existing assays, Dr. Evans and her research team turned their attention to a more targeted method: multiplex fluorescent immunocytochemistry.

Unlike standard tests, MF-ICC solves the specificity problem by leveraging cellular markers. The assay utilizes fluorescent antibodies to simultaneously detect two targets: feline coronavirus antigen and vimentin, a distinct cellular marker that identifies macrophages. Macrophages are the primary cell type housing and spreading the systemic FIP virus.

By superimposing digital images taken at different wavelengths, laboratory personnel can determine whether both the viral antigen and the macrophage marker reside within the exact same cell.

"The innovation we added was multiplexing [the viral marker] with another marker for cellular antigen called vimentin," explains Dr. Evans, associate professor of clinical pathology at Colorado State University (CSU). "That cellular marker allows us to look specifically at macrophages, which are the hallmark cell type of FIP."

By confirming that viral antigen is safely sequestered inside macrophage-like cells—rather than simply floating freely or indicating a local enteric infection—clinicians gain robust evidence of systemic FIP. Best of all, samples can be gathered via minimally invasive procedures, such as drawing effusion fluid from the abdomen or performing a fine-needle aspirate of affected tissues, frequently bypassing the need for general anesthesia.

Supporting Context & Metrics: Inside the Clinical Trial

To rigorously test the efficacy of MF-ICC, the research team designed a robust clinical trial encompassing 84 cats: 58 confirmed FIP cases and 26 controls suffering from alternative pathologies.

Researchers stacked MF-ICC head-to-head against three established diagnostic benchmarks: RT-PCR, serology, and the serum albumin-to-globulin ratio. Final case determinations were meticulously verified through necropsy with histopathology and immunohistochemistry, documented clinical responses to antiviral treatment, and thorough long-term clinical follow-up.

Key Performance Metrics

Using a diagnostic threshold of at least one cell staining positive for both the viral antigen and the vimentin marker, MF-ICC delivered striking statistical performance:

• Sensitivity: 77%
• Specificity: 81%
• Positive Predictive Value (PPV): 92%
• Negative Predictive Value (NPV): 53%
• Overall Accuracy: 78%

For comparison, within this specific cohort, the overall diagnostic accuracy stood at 76% for the serum albumin-to-globulin ratio, 75% for serology, and 69% for RT-PCR.

Surprising Revelations and Nuanced Results

One of the most startling discoveries during the trial caught Dr. Evans completely off guard. Researchers found that the presence of a single dual-positive cell was sufficient to achieve peak diagnostic accuracy.

"Literally a single virus-infected cell was enough information to discriminate FIP versus non-FIP disease," Dr. Evans notes. "It was surprising to me that little material was clinically significant."

The assay’s performance also varied depending on the sample type and clinical presentation of the disease:

• Effusion Fluid vs. Tissue: MF-ICC demonstrated higher sensitivity but slightly lower specificity when performed on effusion fluid. Conversely, in tissue samples taken from cats battling the notoriously difficult-to-diagnose non-effusive (dry) form of FIP, a positive result carried immense diagnostic weight.
• Complementary, Not Competitive: Crucially, the assays did not always flag the exact same feline patients. "MF-ICC picked up some FIP cases that PCR did not, and PCR picked up some FIP cases that MF-ICC did not," Dr. Evans explains. "There is value to ordering both. You’ll have a greater chance of picking up an FIP case by submitting both, and the same sample type can be used for these different assays in a complementary way."

While a positive MF-ICC result strongly bolsters an FIP diagnosis, experts caution that a negative result cannot reliably rule out the disease. Factors such as sample selection, disease distribution, and phenotype matter immensely. For instance, cats presenting with neurological or ocular FIP may harbor virus concentrated in anatomical sites that are extremely difficult to safely sample via needle aspiration.

Official Statements: Perspectives from the Front Lines

The clinical implications of this research extend far beyond the laboratory. Veterinary specialists who contributed to the study emphasize that accelerated, accurate diagnostics are a matter of life and death in modern veterinary practice.

Time Is of the Essence

Benjamin Curtis, DVM, DACVP, clinical assistant professor with the University of Michigan’s Unit for Laboratory Animal Medicine Pathology Core and a co-author of the study, underscores the minimal invasiveness and high clinical utility of the assay.

"It’s minimally invasive," Dr. Curtis says. "Pulling fluid out of the belly or doing a needle aspirate is much less invasive than needing to do a tissue biopsy. But then it brings in the gold-standard concept of immunohistochemistry, in that we can confirm there is viral antigen inside the cells that matches the presentation of FIP."

Because severely compromised FIP patients often have days—rather than weeks—left for a clinical care team to intervene, turnaround speed is paramount. "Having something with a rapid turnaround is going to be life and death for a lot of cats," Dr. Curtis adds. "Being able to get a rapid answer lets owners and veterinarians know whether we need to start moving on treatment or make other decisions."

The Danger of Misdiagnosis and Mismanagement

Petra Černá, PhD, DACVIM (SAIM), Dipl. ECVIM-CA, DABVP (Feline), MANZCVS, an assistant professor of small animal internal medicine at the University of Georgia and a study co-author, has witnessed firsthand the clinical fallout of diagnostic uncertainty. She frequently treats patients that have undergone weeks of misguided antiviral therapy.

"It is very important to have access to fast and accurate diagnostic tests so we can confidently treat these cats," Dr. Černá stresses. "Very often, I see cases that have been treated for several weeks with antiviral therapy, and they do not have FIP. That is not good antiviral stewardship, but we are also missing the actual diagnosis and are not able to help these patients."

For general practitioners juggling complex caseloads, MF-ICC offers a pragmatic safety net. It serves as an invaluable asset when cytology samples have already been drawn, when no material was preserved for RT-PCR, or when a PCR test returns negative despite clinical signs that stubbornly point toward FIP.

Future Outlook: Building a Comprehensive Diagnostic Ecosystem

MF-ICC is not currently designed to be an in-clinic, point-of-care rapid test. Performing the assay requires specialized laboratory equipment to concentrate cells onto slides, specialized fluorescent reagents, and the trained eye of a veterinary pathologist to interpret complex staining patterns.

Recognizing this, Colorado State University intends to make the assay commercially available through its Veterinary Diagnostic Laboratory, continuously evaluating its real-world performance as field submissions accumulate.

Toward a Multi-Pronged Diagnostic Service

Looking ahead, Dr. Evans envisions MF-ICC anchoring a broader, multi-tiered FIP diagnostic service. Rather than relying on a single data point, CSU plans to package MF-ICC alongside PCR, serum biochemistry metrics (such as albumin-to-globulin ratios), and comprehensive patient history profiles.

Simultaneously, researchers are developing sophisticated machine-learning tools driven by routine Complete Blood Count (CBC) and serum biochemistry findings. Backed by CSU’s developing FIP biobank and digital repository, these tools will empower retrospective evaluations as long-term patient outcomes are tracked.

Furthermore, because the published methodology is non-proprietary, other veterinary diagnostic laboratories equipped with the appropriate hardware and expertise can readily acquire the required antibodies and reagents. Broader institutional adoption will inevitably reduce shipping bottlenecks, lower shipping distances, and accelerate turnaround times for practitioners nationwide.

Navigating the Next Wave of FIP Research

As diagnostics improve and survival rates climb, veterinary medicine faces an entirely new frontier of clinical questions. Dr. Černá points out that future research must pivot toward understanding and managing complex patient comorbidities:

• Treatment Failures: Investigating why certain patients fail to respond adequately to antivirals, particularly critically ill cats struggling with severe systemic inflammation, suspected viral sepsis, immune-mediated hemolytic anemia, myocarditis, or concurrent infections.
• Long-Term Sequelae: Tracking recovered patients over years to understand post-treatment health. Clinicians have already noted isolated cases where recovered cats later develop gastrointestinal disorders or large-cell lymphoma—long-term health questions that were impossible to study when FIP was universally fatal.

Ultimately, the overarching message for veterinary professionals is clear. FIP is no longer an insurmountable tragedy, but diagnosing it remains an exercise in clinical puzzle-solving. By combining advanced laboratory assays like MF-ICC with rigorous clinical evaluation, the veterinary community is steadily moving closer to the ultimate goal: a rapid, minimally invasive diagnostic standard that provides definitive answers within hours, saving countless feline lives.

About the Author

A graduate of the University of Miami, Keith Loria is a D.C.-based, award-winning journalist who has spent nearly two decades writing for major publications on topics as diverse as veterinary medicine, travel, and entertainment. Loria began his career with the Associated Press and has held senior editorial positions at prominent publications focused on healthcare, sports, and technology.